GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Immunovia AB (OSTO:IMMNOV) » Definitions » Enterprise Value

Immunovia AB (OSTO:IMMNOV) Enterprise Value : kr30.08 Mil (As of May. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Immunovia AB Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Immunovia AB's Enterprise Value is kr30.08 Mil. Immunovia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-262.43 Mil. Therefore, Immunovia AB's EV-to-EBIT ratio for today is -0.11.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Immunovia AB's Enterprise Value is kr30.08 Mil. Immunovia AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-123.80 Mil. Therefore, Immunovia AB's EV-to-EBITDA ratio for today is -0.24.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Immunovia AB's Enterprise Value is kr30.08 Mil. Immunovia AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 was kr1.21 Mil. Therefore, Immunovia AB's EV-to-Revenue ratio for today is 24.81.


Immunovia AB Enterprise Value Historical Data

The historical data trend for Immunovia AB's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovia AB Enterprise Value Chart

Immunovia AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,304.72 2,262.36 1,443.22 526.74 7.75

Immunovia AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 128.65 -40.84 -45.93 7.75 19.57

Competitive Comparison of Immunovia AB's Enterprise Value

For the Diagnostics & Research subindustry, Immunovia AB's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovia AB's Enterprise Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Immunovia AB's Enterprise Value falls into.



Immunovia AB Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Immunovia AB's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Immunovia AB's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunovia AB  (OSTO:IMMNOV) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Immunovia AB's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=30.075/-262.425
=-0.11

Immunovia AB's current Enterprise Value is kr30.08 Mil.
Immunovia AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-262.43 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Immunovia AB's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=30.075/-123.798
=-0.24

Immunovia AB's current Enterprise Value is kr30.08 Mil.
Immunovia AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-123.80 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Immunovia AB's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=30.075/1.212
=24.81

Immunovia AB's current Enterprise Value is kr30.08 Mil.
Immunovia AB's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunovia AB Enterprise Value Related Terms

Thank you for viewing the detailed overview of Immunovia AB's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovia AB (OSTO:IMMNOV) Business Description

Traded in Other Exchanges
Address
Medicon Village, Scheelevagen 8, Lund, SWE, 223 63
Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The group's intangible and tangible assets are in Sweden, in the United States and in Germany.

Immunovia AB (OSTO:IMMNOV) Headlines

No Headlines